Coiled Therapeutics, a clinical-stage oncology company, has begun trading on the US OTCQB Venture Market under the ticker COTXF, allowing US investors to buy shares in dollars during US market hours. This move aims to improve liquidity and broaden its shareholder base while maintaining its AIM listing. The company recently reported an 80% clinical benefit rate in its ongoing cancer trial, with dose escalation expected to complete in early 2026 and multiple data updates anticipated throughout the year. CEO Sridhar Vempati views 2026 as a transformational year for Coiled Therapeutics.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
